Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2025)

Stoke Therapeutics has reported Non-Current Deffered Revenue over the past 4 years, most recently at $7.0 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, changed N/A, while the annual FY2025 figure was $7.0 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $7.0 million at Stoke Therapeutics, down from $8.6 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $49.5 million in Q1 2022 and troughed at $7.0 million in Q4 2025.
  • A 4-year average of $27.3 million and a median of $33.1 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 79.64% in 2024 and later rose 3.22% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $36.9 million in 2022, then decreased by 10.26% to $33.1 million in 2023, then tumbled by 74.93% to $8.3 million in 2024, then decreased by 16.04% to $7.0 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for STOK at $7.0 million in Q4 2025, $8.6 million in Q3 2025, and $9.6 million in Q2 2025.